Antiidiotypic antibodies carrying the "internal image" of peptide YIGSR inhibit spontaneous metastasis of Lewis lung carcinoma in mice.
BACKGROUND
It has been reported that the laminin derivative synthetic peptide YIGSR can bind to a metastasis-associated laminin receptor and inhibit experimental metastasis. Several antiidiotypic antibody (anti-Id) vaccines have been used in clinical trials with promising results. We used an anti-Id vaccine based on peptide YIGSR for the inhibition of spontaneous metastasis in Lewis Lung carcinoma-bearing mice.


METHODS
High titer anti-YIGSR serum from immunized rabbits was used to immunize sixteen Lewis Lung Carcinoma (LLC)-bearing mice. Another group of sixteen mice (controls) inoculated with LLC was immunized with control rabbit serum. After 24 days of tumor growth, the volume of the tumor was estimated, a blood sample was collected and the lungs were examined macroscopically and microscopically for metastasis. The presence of anti-Id antibodies was detected by Western blotting, ELISA and inhibition of cell attachment assays.


RESULTS
Tumor growth was limited and metastasis was inhibited in the mice that received the anti-Id YIGSR vaccine as compared to controls. Both groups of mice developed anti-rabbit antibodies as indicated by Western blotting. However only the serum of mice immunized with high titer anti-YIGSR rabbit serum (anti-Id YIGSR vaccine) could inhibit the binding of the anti-YIGSR rabbit serum to the peptide YIGSR in ELISA assays. In addition the serum of mice that received the anti-Id YIGSR vaccine but not the controls inhibited cell attachment to the peptide on solid face assays.


CONCLUSIONS
An anti-Id antimetastatic vaccine may be developed based on YIGSR.
Koliakos
Kokkona Kouzi
KK
Department of Histology and Embryology, Medical School Aristotle University, 54006 Thessaloniki, Greece.
Sapountzi
Zacharoula
Z
Papageorgiou
Athanassios
A
Trachana
Varvara
V
Kotsinou
Sophia
S
Koliakos
George
G
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D015153:Blotting, Western; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary; D007797:Laminin / Q000276:immunology*; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009842:Oligopeptides / Q000276:immunology*; D011817:Rabbits
D000888:Antibodies, Anti-Idiotypic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007797:Laminin; D009842:Oligopeptides; C081571:tyrosyl-isoleucyl-glycyl-seryl-arginine